Proof of Concept: Drug Selection? Or Dose Selection? Thoughts on Multiplicity Issues

por Li, Qian H., Deng, Qiqi, Ting, Naitee
Publicado 2021

Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score–Matched Analysis of...

por Schwartz, Gregory G., Gabriel Steg, Philippe, Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Jukema, J. Wouter, Kim, Yong-Un, Li, Qian H., Manvelian, Garen, Pordy, Robert, Sourdille, Timothée, White, Harvey D., Szarek, Michael
Publicado 2021

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OU...

por Tuñón, José, Steg, Philippe Gabriel, Bhatt, Deepak L, Bittner, Vera A, Díaz, Rafael, Goodman, Shaun G, Jukema, J Wouter, Kim, Yong-Un, Li, Qian H, Mueller, Christian, Parkhomenko, Alexander, Pordy, Robert, Sritara, Piyamitr, Szarek, Michael, White, Harvey D, Zeiher, Andreas M, Schwartz, Gregory G
Publicado 2020

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acu...

por Roe, Matthew T., Li, Qian H., Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Harrington, Robert A., Jukema, J. Wouter, Lopez-Jaramillo, Patricio, Lopes, Renato D., Louie, Michael J., Moriarty, Patrick M., Szarek, Michael, Vogel, Robert, White, Harvey D., Zeiher, Andreas M., Baccara-Dinet, Marie T., Steg, Ph. Gabriel, Schwartz, Gregory G.
Publicado 2019